ArticleJournal of extracellular biology2026
Molecular Characterization of Extracellular Vesicles From Human B Cell Lymphomas: Methodological Comparison to Vesicles From Patient Serum.
Article in Journal of extracellular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human B cell lymphomas represent a clinically heterogeneous disease group with lack of liquid biomarkers for specific subtype classification. Extracellular vesicles (EVs) hold promises as non-invasive biomarkers, yet their subtype-specific characteristics and clinical utility in these diseases remain largely underexplored. In this study, we have investigated the basic molecular and physical features of EVs from diffuse large B cell lymphoma (DLBCL) cells and from lymphoma patients' serum. Data from e.g., electron microscopy (EM), Western blotting (WB), immunoassay and mass spectrometry (MS) revealed that the two main DLBCL cell subtype EVs differ in protein expression profile and in overall EV size, with the ABC (Activated B Cell) type having smaller EVs than the GCB (Germinal Centre B cell) type. The ABC type EVs were found significantly more enriched with tetraspanins CD81 and CD9. Parallel experimentation on lymphoma serum EVs revealed shared markers with lymphoma cell line EVs, and that B cell specific marker CD19 can be detected among other serum EVs. Also, to successfully detect markers, e.g. Hsp70 or CD44, in serum EVs we demonstrated to require more intense sample preparation in specific assays. While more patient studies are needed in the future, this pilot study paves the way for understanding the molecular differences in the DLBCL subtypes and for detecting them in the lymphoma EVs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.